Abstract: FR-PO839
The Effect of Controlled Ovarian Stimulation (COS) on Kidney Health Outcomes: A Protocol
Session Information
- Women's Health and Kidney Diseases
November 03, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Women's Health and Kidney Diseases
- 2200 Women's Health and Kidney Diseases
Authors
- Kharbanda, Sakshi, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada
- Ahmed, Sofia B., University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada
- Foong, Shu, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada
- Riehl-Tonn, Victoria J., University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada
- Dumanski, Sandi M., University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada
Background
The prevalence of chronic kidney disease (CKD) in females is >12% and prevention of CKD is a patient-identified research priority. Females face unique risks to their kidney health, and exogenous hormone use (hormone replacement therapy and contraceptives) has been implicated in kidney risk. However, there is a paucity of data on how exogenous hormone use in controlled ovarian stimulation (COS), commonly utilized in fertility treatment and preservation, affects kidney health.This prospective study will examine the effect of COS on kidney health outcomes, including 1) filtration fraction (FF), 2) glomerular filtration rate (GFR), and 3) kidney plasma flow (KPF).
Methods
Healthy females treated with COS will be recruited from the fertility clinic in Calgary, Canada to participate in 2 study days in the research laboratory. Study Day #1 will be a baseline visit immediately prior to initiation of COS treatment and Study Day #2 will be completed at the peak of the hormone administration phase of COS. On each study day, serum hormone levels will be measured. Using standardized protocols, participants will receive intravenously-administrated iohexol and para-aminohippurate and subsequent plasma monitoring to determine GFR and KPF, respectively. FF will be calculated as follows: GFR/KPF.
Results
Using a paired non-paramtric student t-test such as the Wilcoxon signed rank test, changes in GFR, KPF and FF will be compared between between Study Day #1 and Study Day #2.
Conclusion
The prevalence of CKD in females is increasing rapidly, highlighting the urgency of preventative interventions. COS treatment is common, and this research will elucidate the relationship between COS and kidney health, inform future studies, and empower females and their care providers in their reproductive choices.
Funding
- Government Support – Non-U.S.